With Drs. Ingmar Gorman, & Elizabeth Nielson
1-Day Pre-Conference Workshop of Beyond Psychedelics 2018 June 19, Prague
What is psychedelic harm reduction and integration and how can they occur in a clinical setting? This day long training offered by psychologists Ingmar Gorman PhD and Elizabeth Nielson PhD is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice. We will focus on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues.
Ingmar Gorman, Ph.D., is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Director of the Psychedelic Education and Continuing Care Program at The Center for Optimal Living, where he leads groups, trainings, and works with individual clients. Dr. Gorman is also site co-principal Investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for post-traumatic stress disorder. He is a NIH funded fellow at New York University and a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics.
Elizabeth M. Nielson, PhD, CASAC, is a psychologist at the Psychedelic Education and Continuing Care Program at The Center for Optimal Living where she specializes in individual and group psychedelic harm reduction and integration psychotherapy. Dr. Nielson received her PhD in Clinical Psychology from Walden University and completed an NIH-funded post-doctoral fellowship at NYU. Dr. Nielson is presently a therapist on the phase 2 trials of psilocybin-assisted treatment of alcohol dependence and of MDMA-assisted treatment of PTSD at NYU School of Medicine. Dr. Nielson’s own program of research includes qualitative studies of patient experiences in psilocybin research trials, psychedelic therapists’ experiences and methods, and the historical use of LSD as a training experience for therapists.